Olivia J. S. Macleod

Olivia J. S. Macleod

Auto-generated profile, based on publicly available information

Olivia J. S. Macleod

Department of Biochemistry, University of Cambridge

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 December 2015 in PLOS Pathogens
Verified
Journal Article
Open access
PDF file
ASAngela Schwede
Angela Schwede
OMOlivia J S Macleod
Olivia J S Macleod
PMPaula MacGregor
Paula MacGregor
MCMark Carrington
Mark Carrington
Variations on the statement “the variant surface glycoprotein (VSG) coat that covers the external face of the mammalian bloodstream form of Trypanosoma brucei acts a physical barrier” appear regularly in research articles and reviews. The concept of the impenetrable VSG coat is an attractive one, as it provides a clear model for understanding how a trypanosome population persists; each successive VSG protects the plasma membrane and is immunologically distinct from previous VSGs. What is the evidence that the VSG coat is an impenetrable barrier, and how do antibodies and other extracellular proteins interact with it? In this review, the nature of the extracellular surface of the bloodstream form trypanosome is described, and past experiments that investigated binding of antibodies and lectins to trypanosomes are analysed using knowledge of VSG sequence and structure that was unavailable when the experiments were performed. Epitopes for some VSG monoclonal antibodies are mapped as far as possible from previous experimental data, onto models of VSG structures. The binding of lectins to some, but not to other, VSGs is revisited with more recent knowledge of the location and nature of N-linked oligosaccharides. The conclusions are: (i) Much of the variation observed in earlier experiments can be explained by the identity of the individual VSGs. (ii) Much of an individual VSG is accessible to antibodies, and the barrier that prevents access to the cell surface is probably at the base of the VSG N-terminal domain, approximately 5 nm from the plasma membrane. This second conclusion highlights a gap in our understanding of how the VSG coat works, as several plasma membrane proteins with large extracellular domains are very unlikely to be hidden from host antibodies by VSG. African trypanosomes have evolved two key strategies to prevent killing by the host immune response and, thus, maintain a long-term infection in a mammal. Both are based on a densely packed coat of a single protein, the variant surface glycoprotein (VSG), which covers the entire extracellular surface of the cell. The first strategy is antigenic variation, through which individual cells switch the identity of the expressed VSG at a low frequency and are selected by the host immune response. If the VSG is novel, the trypanosome proliferates, maintaining the infection; if it doesn't switch, or if the new VSG is not novel, it will be killed. In the second strategy, the VSG acts as a protective barrier, shielding the cell from innate and adaptive immune factors until there is an overwhelming titre of antibodies recognising the expressed VSG. In this review, the VSG coat is modelled, and past experiments that investigated how it protected the trypanosome are revisited using current knowledge of VSG sequence and structure. The conclusions are: (i) the identity of the individual VSGs explains early experimental variation; (ii) most of the VSG molecule is accessible to antibodies. This second conclusion highlights a gap in our understanding of how the VSG coat works, as several plasma membrane proteins with large extracellular domains are very unlikely to be hidden from host antibodies by VSG.

1 August 2017 in Genome Biology and Evolution
Verified
Journal Article
Open access
PDF file
SKSteven Kelly
Steven Kelly
AIAlasdair Ivens
Alasdair Ivens
GMG. Adam Mott
G. Adam Mott
Ellis O'NeillEllis O'Neill
Ellis O'Neill
DEDavid Emms
David Emms
MCMark Carrington
Mark Carrington
There are hundreds of Trypanosoma species that live in the blood and tissue spaces of their vertebrate hosts. The vast majority of these do not have the ornate system of antigenic variation that has evolved in the small number of African trypanosome species, but can still maintain long-term infections in the face of the vertebrate adaptive immune system. Trypanosoma theileri is a typical example, has a restricted host range of cattle and other Bovinae, and is only occasionally reported to cause patent disease although no systematic survey of the effect of infection on agricultural productivity has been performed. Here, a detailed genome sequence and a transcriptome analysis of gene expression in bloodstream form T. theileri have been performed. Analysis of the genome sequence and expression showed that T. theileri has a typical kinetoplastid genome structure and allowed a prediction that it is capable of meiotic exchange, gene silencing via RNA interference and, potentially, density-dependent growth control. In particular, the transcriptome analysis has allowed a comparison of two distinct trypanosome cell surfaces, T. brucei and T. theileri, that have each evolved to enable the maintenance of a long-term extracellular infection in cattle. The T. theileri cell surface can be modeled to contain a mixture of proteins encoded by four novel large and divergent gene families and by members of a major surface protease gene family. This surface composition is distinct from the uniform variant surface glycoprotein coat on African trypanosomes providing an insight into a second mechanism used by trypanosome species that proliferate in an extracellular milieu in vertebrate hosts to avoid the adaptive immune response.

12 March 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
OMOlivia J. S. Macleod
Olivia J. S. Macleod
Jean-Mathieu BartJean-Mathieu Bart
Jean-Mathieu Bart
PMPaula MacGregor
Paula MacGregor
LPLori Peacock
Lori Peacock
NSNicholas J. Savill
Nicholas J. Savill
MCMark Carrington
Mark Carrington
Persistent pathogens have evolved to avoid elimination by the mammalian immune system including mechanisms to evade complement. Infections with African trypanosomes can persist for years and cause human and animal disease throughout sub-Saharan Africa. It is not known how trypanosomes limit the action of the alternative complement pathway. Here we identify an African trypanosome receptor for mammalian factor H, a negative regulator of the alternative pathway. Structural studies show how the receptor binds ligand, leaving inhibitory domains of factor H free to inactivate complement C3b deposited on the trypanosome surface. Receptor expression is highest in developmental stages transmitted to the tsetse fly vector and those exposed to blood meals in the tsetse gut. Receptor gene deletion reduced tsetse infection, identifying this receptor as a virulence factor for transmission. This demonstrates how a pathogen evolved a molecular mechanism to increase transmission to an insect vector by exploitation of a mammalian complement regulator.

29 August 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
OMOlivia J. S. Macleod
Olivia J. S. Macleod
ACAlexander D. Cook
Alexander D. Cook
HWHelena Webb
Helena Webb
MCMandy Crow
Mandy Crow
RBRoisin Burns
Roisin Burns
MCMark Carrington
Mark Carrington
African trypanosomes are extracellular pathogens of mammals and are exposed to the adaptive and innate immune systems. Trypanosomes evade the adaptive immune response through antigenic variation, but little is known about how they interact with components of the innate immune response, including complement. Here we demonstrate that an invariant surface glycoprotein, ISG65, is a receptor for complement component 3 (C3). We show how ISG65 binds to the thioester domain of C3b. We also show that C3 contributes to control of trypanosomes during early infection in a mouse model and provide evidence that ISG65 is involved in reducing trypanosome susceptibility to C3-mediated clearance. Deposition of C3b on pathogen surfaces, such as trypanosomes, is a central point in activation of the complement system. In ISG65, trypanosomes have evolved a C3 receptor which diminishes the downstream effects of C3 deposition on the control of infection.

21 October 2019 in Nature Microbiology
Verified
Journal Article
Closed access
PDF file
CTCamilla E. Trevor
Camilla E. Trevor
AGAndrea L. Gonzalez-Munoz
Andrea L. Gonzalez-Munoz
OMOlivia J. S. Macleod
Olivia J. S. Macleod
PWPeter G. Woodcock
Peter G. Woodcock
SRSteven Rust
Steven Rust
MHMatthew K. Higgins
Matthew K. Higgins

23 May 2019 in PLOS Neglected Tropical Diseases
Verified
Journal Article
Open access
PDF file
PMPaula MacGregor
Paula MacGregor
AGAndrea L Gonzalez-Munoz
Andrea L Gonzalez-Munoz
FJFatoumatta Jobe
Fatoumatta Jobe
MTMartin Taylor
Martin Taylor
SRSteven Rust
Steven Rust
MCMark Carrington
Mark Carrington
Infections of humans and livestock with African trypanosomes are treated with drugs introduced decades ago that are not always fully effective and often have severe side effects. Here, the trypanosome haptoglobin-haemoglobin receptor (HpHbR) has been exploited as a route of uptake for an antibody-drug conjugate (ADC) that is completely effective against Trypanosoma brucei in the standard mouse model of infection. Recombinant human anti-HpHbR monoclonal antibodies were isolated and shown to be internalised in a receptor-dependent manner. Antibodies were conjugated to a pyrrolobenzodiazepine (PBD) toxin and killed T. brucei in vitro at picomolar concentrations. A single therapeutic dose (0.25 mg/kg) of a HpHbR antibody-PBD conjugate completely cured a T. brucei mouse infection within 2 days with no re-emergence of infection over a subsequent time course of 77 days. These experiments provide a demonstration of how ADCs can be exploited to treat protozoal diseases that desperately require new therapeutics. Here we show that antibody-drug conjugates (ADCs) can be re-purposed from cancer immunotherapeutics to anti-protozoals by changing the specificity of the immunoglobulin to target a trypanosome cell surface receptor. Trypanosomes were used as a model system due to the availability of receptor null cell lines that allowed the unambiguous demonstration that ADCs targeted to a parasite surface receptor could be specifically internalised via receptor-mediated endocytosis. A single low dose of the resulting ADC was able to cure a stage 1 mouse model of trypanosome infection. We have used toxins and conjugation chemistry that are identical to anti-cancer ADCs demonstrating the ability to piggy-back onto the huge research efforts and resources that are being invested in the development of such ADCs. The potential for development of ADCs against a wide range of human pathogens is vast, where only epitope binding sites need vary in order to provide selectivity. This provides a far-reaching opportunity for the rapid development of novel anti-protozoals for the targeted killing of a wide range of pathogens that cause disease worldwide, especially in developing countries.